Halozyme Therapeutics Inc. | Ownership
Companies that own Halozyme Therapeutics Inc.
The Vanguard Group, Inc.
12,431,440
8.61%
646,897
0.01%
06/30/2018
BlackRock Fund Advisors
9,688,271
6.71%
525,438
0.01%
06/30/2018
Iridian Asset Management LLC
8,260,476
5.72%
68,098
1.39%
06/30/2018
Bellevue Asset Management AG
8,247,860
5.72%
-348,077
2.19%
06/30/2018
SSgA Funds Management, Inc.
4,575,701
3.17%
-423,017
0.01%
06/30/2018
Invesco Advisers, Inc.
3,716,982
2.58%
-40,044
0.04%
06/30/2018
Pictet Asset Management SA
2,640,762
1.83%
172,434
0.06%
06/30/2018
Fidelity Management & Research Co.
2,473,181
1.71%
0
0.01%
06/30/2018
Snyder Capital Management LP
2,375,876
1.65%
23,351
1.91%
06/30/2018
Thrivent Investment Management, Inc.
2,316,137
1.61%
2,316,137
0.13%
06/30/2018
| Address |
11388 Sorrento Valley Road
San Diego California 92121
United States
|
|
Employees
|
- |
| Website |
http://www.halozyme.com |
| Updated |
07/08/2019 |
| Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. |
